Source: Eur Respir J, 51 (1) 1702024; 10.1183/13993003.02024-2017
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Simone H.J. van den Elsen, Onno W. Akkerman, Justine R. Huisman, Daan J. Touw, Tjip S. van der Werf, Mathieu S. Bolhuis, Jan-Willem C. Alffenaar. Lack of penetration of amikacin into saliva of tuberculosis patients. Eur Respir J, 51 (1) 1702024; 10.1183/13993003.02024-2017

Member's Comments

No comment yet.

Related content which might interest you: Pharmacokinetics of ertapenem in patients with multidrug-resistant tuberculosis Source: Eur Respir J 2016; 47: 1229-1234 Year: 2016 Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013 Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601724; DOI: 10.1183/13993003.01724-2016 Year: 2017 Comparison of moxifloxacin and ofloxacin in treatment of multidrug resistant pulmonary tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis Source: Eur Respir J, 51 (2) 1702166; 10.1183/13993003.02166-2017 Year: 2018 Reduced moxifloxacin exposure in patients with tuberculosis and diabetes Source: Eur Respir J, 54 (3) 1900373; 10.1183/13993003.00373-2019 Year: 2019 Amoxicillin concentrations in sputum in relation to betalactamase activity in COPD patients Source: Annual Congress 2011 - Role of infection in exacerbations of COPD Year: 2011 Comparison of conventional and sequential antibiotic therapy of community-acquired pneumonia with levofloxacin and moxifloxacin Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 In vitro activity of moxifloxacin and linezolid against mycobacteria Source: Annual Congress 2008 - Genetics, immunology and microbiology of tuberculosis Year: 2008 Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021 Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection in which Streptococcus pyogenes was isolated in sputum culture Source: Eur Respir J 2004; 24: Suppl. 48, 414s Year: 2004 Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance Source: Eur Respir J, 50 (1) 1700598; 10.1183/13993003.00598-2017 Year: 2017 Detection of isoniazid or rifampin resistant Mycobacterium tuberculosis in patients with cavity and previously treated for tuberculosis - usefulness of rapid drug susceptibility test with sputum samples by reverse hybridization assay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005 Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience Source: Eur Respir J 2011; 38: 888-894 Year: 2011 Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients Source: Eur Respir J, 53 (4) 1802107; 10.1183/13993003.02107-2018 Year: 2019 The role of moxifloxacin in tuberculosis therapy Source: Eur Respir Rev 2015; 25: 19-28 Year: 2016 Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2013; 42: 504-512 Year: 2013 In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis Source: Eur Respir J 2014; 44: 808-811 Year: 2014 Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013